Navigation Links
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
Date:6/11/2008

of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Quarterly Report on Form 10-Q for the period ended March 31, 2008, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Glenn Schulman, PharmD

Director of Medical Communications

gschulman@curagen.com

(888) 436-6642

CRGN-P


'/>"/>
SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... August 28, 2015 The report "Eubiotics Market by ... Poultry, Ruminant, and Aquaculture), & by Region ( North ... Asia-Pacific , and Rest of the World) - Global ... market for Eubiotics was valued at USD 4.62 Billion in ... 2020, at a CAGR of 7.4% from 2015 to 2020. ...
(Date:8/27/2015)...  A recent study by Feucht et al, ... Arthrosurface HemiCAP® Wave implant, which is based on ... implant for isolated patellofemoral disease. While both implant ... scores, none of the patients in the "inlay" ... of the patients in the "onlay" group, showed ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... May 12, 2011 Polaris Group (Polaris) today announced ... its Phase 3-ready pegylated arginine deiminase, ADI-PEG 20, during ... p.m. China Standard Time in Taipei, Taiwan. ... of ADI-PEG 20 in hepatocellular carcinoma (HCC) will be ...
... SANTA CLARA, Calif., May 12, 2011 Cell Biosciences, ... Inc. of Ottawa, Ontario for approximately U.S. $9 million ... market leader in Micro-Flow Imaging (MFI), an analytical technique ... Because of high interest in protein aggregation expressed by ...
Cached Medicine Technology:Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan 2Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan 3Cell Biosciences Acquires Brightwell Technologies 2
(Date:8/30/2015)... ... ... Natural Rest contains a unique mixture of vitamins and herbs that are ... to improve mood disorders and anxiety. Like all other Creative Medical Health products, Natural ... regenerative medicine conducted by Dr. Amit Patel of the University of Utah, one of ...
(Date:8/30/2015)... ... 30, 2015 , ... SonaCare Medical, LLC, the makers of ... cancer, has announced the roll-out of its newest technology – called Sonafuse ... Mexico. , The Sonablate® technology currently in use at the San Javier Marina ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, ... Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your ... lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 ...
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is ... chiropractic field in the military. All too often VA hospitals treat patients with harmful ... to the VA program over a decade ago, the reality is that only 10% ...
(Date:8/29/2015)... AB (PRWEB) , ... August 29, 2015 , ... ... heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are at ... such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia or ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2
... first U.S. clinical trial using genetic screening to ... therapies supports the use of those drugs as ... failed. While the study led by Massachusetts General ... (Iressa) treatment considerably improved the outcomes for non-small-cell-lung-cancer ...
... at the University of Illinois report this week that a ... can disrupt a key component of the inflammatory response in ... and diseases such as Alzheimers and multiple sclerosis. , ... Academy of Sciences. , Inflammation can be a blessing or ...
... the ... chance to change people,s lives, OTTAWA, May 20 ... for new ways to make the most of their,time, especially ... independent marketing opportunities provided by,Melaleuca, The Wellness Company(R)., One ...
... Anthem,s Care Comparison Tool Gives Members the Most Complete Picture ... Costs Associated with Medical ... Cross and,Blue Shield (Anthem) announced today the expansion of its ... access,to Anthem Care Comparison, an online tool that provides total ...
... WASHINGTON, May 20 Wednesday, May 21, 2008,Easter Seals ... Senator Mary Landrieu and Capital One for,their efforts on ... Advocacy Awards Benefit will be held at the JW ... pm and dinner at 7:00,pm. Gordon Peterson of WJLA ...
... May 20 Despite the clear benefits of,lipid-modifying ... in a new supplement to The Journal of ... aggressive,lipid lowering" reviews the evidence from recent trials ... and the use of,statins to improve outcomes in ...
Cached Medicine News:Health News:Determining genetic signature of lung tumors can help guide treatment 2Health News:Determining genetic signature of lung tumors can help guide treatment 3Health News:Plant flavonoid found to reduce inflammatory response in the brain 2Health News:Plant flavonoid found to reduce inflammatory response in the brain 3Health News:Lucrative Sales Opportunities Abound With Melaleuca, The Wellness Company(R) 2Health News:Anthem Blue Cross and Blue Shield Introduces Transparency Initiative in Maine 2Health News:Anthem Blue Cross and Blue Shield Introduces Transparency Initiative in Maine 3Health News:Reductions in CV Morbidity and Mortality are Achievable! 2
Wellpro 96 an automated liquid handling system for 96-well plates that quickly and accurately prepares large quantities of serial dilutions. The Wellpro also performs plate to plate transfers using ...
... Recovery with The aliquot! The aliquot from ... dispenser compatible with 96, 384, and 1536 ... dispensing action, backfilling facility and optional microplate ... to your low volume dispensing needs. The ...
... 384 is a compact and self-contained ... is a unique flow-through device, which ... included wash system. Optional refill ... system. Will be upgradable to ...
... The Aquarius 96 is a compact and ... optional fixed tip manifold can be used ... efficiently washed in the optional active wash ... to dust and adds safety. ...
Medicine Products: